Fig. 3: Survival analysis in resectable PDAC patients with or without plasma KRAS G12D mutation in the validation cohort. | British Journal of Cancer

Fig. 3: Survival analysis in resectable PDAC patients with or without plasma KRAS G12D mutation in the validation cohort.

From: Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients

Fig. 3

a OS for resectable PDAC patients with (n = 5, red) and without (n = 39, blue) KRAS G12D mutant in ctDNA. b RFS for resectable PDAC patients with (n = 5, red) and without (n = 39, blue) KRAS G12D mutation in ctDNA.

Back to article page